106 related articles for article (PubMed ID: 7788233)
1. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE; Wheldon TE; Gaze MN; Barrett A
Br J Radiol; 1995 May; 68(809):481-90. PubMed ID: 7788233
[TBL] [Abstract][Full Text] [Related]
2. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.
Tristam M; Alaamer AS; Fleming JS; Lewington VJ; Zivanovic MA
J Nucl Med; 1996 Jun; 37(6):1058-63. PubMed ID: 8683301
[TBL] [Abstract][Full Text] [Related]
5. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG.
Bolster AA; Hilditch TE; Wheldon TE
J Nucl Med; 1995 Aug; 36(8):1530-1. PubMed ID: 7629603
[No Abstract] [Full Text] [Related]
7. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
9. The radiation dose to the urinary bladder in radio-iodine therapy.
Bolster AA; Hilditch TE
Phys Med Biol; 1996 Oct; 41(10):1993-2008. PubMed ID: 8912376
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
[TBL] [Abstract][Full Text] [Related]
12. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
13. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
14. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
15. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
17. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
18. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
19. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
Beierwaltes WH
Med Pediatr Oncol; 1987; 15(4):188-91. PubMed ID: 3657705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
